BeiGene, Ltd. (now rebranded as BeOne Medicines) is expected to report Q3 2026 revenue of $1.76 billion and EPS of $2.34, with its current price of $355.84 trailing the analyst consensus target of $437.57.
Investors are primarily focused on the global sales trajectory of Brukinsa, the company's flagship BTK inhibitor, which is anticipated to generate $1.30 billion this quarter.
The report follows the company's transition to sustained GAAP profitability in 2025 and its strategic redomiciliation to Switzerland.
Market watchers will also scrutinize the expansion of the solid tumor portfolio and the regulatory progress of the BCL2 inhibitor sonrotoclax as BeOne seeks to diversify its revenue base beyond hematology.